{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:42:36Z","timestamp":1788302556143,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pcad.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T05:13:15Z","timestamp":1517375595000},"page":"531-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy \u2013 \u201cReal World\u201d Experience"],"prefix":"10.1016","volume":"60","author":[{"given":"Mark B.","family":"Effron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2018.01.010_bb0005","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.010_bb0010","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"The ACTIVE Writing Group","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.010_bb0015","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.pcad.2018.01.010_bb0020","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.010_bb0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/europace\/euu225","article-title":"Non-vitamin K antagonist oral anticoagulation agents in anticoagulant na\u00efve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013","volume":"17","author":"Olesen","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.pcad.2018.01.010_bb0030","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics\u20142017 Update","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.010_bb0035","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0040","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.010_bb0045","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"The Clopidogrel in Unstable angina to prevent Recurrent Events trial investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1540-8183.2009.00468.x","article-title":"Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting","volume":"22","author":"Rubboli","year":"2009","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.pcad.2018.01.010_bb0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jacc.2016.05.085","article-title":"Outcomes of patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"68","author":"Sutton","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.010_bb0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ahj.2003.06.004","article-title":"Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation","volume":"147","author":"Orford","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.010_bb0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1378\/chest.08-0350","article-title":"Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting","volume":"134","author":"Manzano-Fern\u00e1ndez","year":"2008","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pcad.2018.01.010_bb0080","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2796.2008.01989.x","article-title":"Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation","volume":"264","author":"Sarafoff","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjcard.2009.03.053","article-title":"Antiplatelet Therapy in Patients With Anticoagulants Undergoing Percutaneous Coronary Stenting (from STENTIng and oral antiCOagulants [STENTICO])","volume":"104","author":"Gilard","year":"2009","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2018.01.010_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjcard.2015.03.033","article-title":"Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR registry)","volume":"116","author":"Mennuni","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2018.01.010_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004310","article-title":"Use of chronic oral anticoagulation and associated outcomes among patients undergoing percutaneous coronary intervention","volume":"5","author":"Secemsky","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2018.01.010_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ahj.2007.09.003","article-title":"Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry","volume":"155","author":"Wang","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.010_bb0105","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.010_bb0110","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.amjmed.2015.12.026","article-title":"Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease","volume":"129","author":"Lopes","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0120","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study","volume":"8","author":"Jackson","year":"2015","journal-title":"J Am Coll Cardiol Intv"},{"issue":"9872","key":"10.1016\/j.pcad.2018.01.010_bb0125","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.pcad.2018.01.010_bb0130","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.010_bb0135","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.010_bb0140","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.010_bb0145","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2011.08633.x","article-title":"Proton pump inhibitors and the risk of over anticoagulation during acenocoumarol maintenance treatment","volume":"153","author":"Teichert","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T05:10:40Z","timestamp":1530508240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062018300306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":29,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0033062018300306"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.010","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy \u2013 \u201cReal World\u201d Experience","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}